ATI RN
ATI Endocrine Pharmacology Quizlet Questions
Question 1 of 5
Which of the following drugs would be appropriate for local therapy in this patient?
Correct Answer: B
Rationale: The correct answer is B: Norgestrel. Norgestrel is a progestin used for local therapy in this patient because it can be administered directly to the affected area to target specific tissues. Ethinyl estradiol, Anastrozole, and Tamoxifen are not appropriate for local therapy as they are systemic drugs that act throughout the body. Ethinyl estradiol is an estrogen component in combined oral contraceptives, Anastrozole is an aromatase inhibitor used for breast cancer systemically, and Tamoxifen is a selective estrogen receptor modulator used for breast cancer treatment.
Question 2 of 5
A 21-year-old woman complained to her physician of recurrent nausea lasting most of the day. The woman had been suffering from a urinary tract infection presently being treated with ciprofloxacin and from gastroesophageal reflux disease presently being treated with omeprazole. She also routinely took ibuprofen during her menstrual period. One week ago, she started taking a contraceptive pill (ethinyl estradiol and norgestrel). Which of the following drugs most likely caused the patient's nausea?
Correct Answer: C
Rationale: The correct answer is C: Norgestrel. Nausea is a common side effect of contraceptive pills, especially when initially starting them. Norgestrel is a component of the contraceptive pill the patient started one week ago, which aligns with the timing of the onset of her nausea symptoms. Ciprofloxacin and omeprazole are less likely to cause nausea in this case, as the patient has been taking them for some time without issues. Ethinyl estradiol is also a component of the contraceptive pill but is less likely to be the primary cause of the nausea compared to norgestrel.
Question 3 of 5
Which of the following would be an appropriate change in the treatment plan for a patient with osteoporosis and hypertension experiencing a significant decrease in bone mass despite current therapy?
Correct Answer: C
Rationale: The correct answer is C: Add calcitonin to the current regimen. Calcitonin helps to increase bone density and reduce bone loss in osteoporosis. This would address the significant decrease in bone mass. Choice A (substitute hydrochlorothiazide with propranolol) is incorrect as propranolol does not have a direct impact on bone mass. Choice B (substitute raloxifene with ethinyl estradiol) is incorrect as ethinyl estradiol is not typically used for osteoporosis and may not be effective. Choice D (increase the daily dose of calcium carbonate) is incorrect as simply increasing calcium intake may not be sufficient to address the bone loss, especially in the presence of inadequate bone formation. Adding calcitonin addresses the root cause of bone loss in osteoporosis and is therefore the appropriate change in the treatment plan.
Question 4 of 5
Which one of the following compounds is not a hormone?
Correct Answer: A
Rationale: In this question from the ATI Endocrine Pharmacology Quizlet, the correct answer is A) Bromocriptine. Bromocriptine is not a hormone; it is a dopamine receptor agonist used to treat conditions like hyperprolactinemia and Parkinson's disease. It does not directly function as a hormone within the endocrine system. On the other hand, options B, C, and D are all hormones. Somatomedin (option B) is a hormone that mediates the effects of growth hormone, while somatotropin (option C) is another name for growth hormone itself. Thyroxine (option D) is a hormone produced by the thyroid gland that regulates metabolism. Understanding the distinction between hormones and other pharmacological agents is crucial in the field of endocrine pharmacology. This knowledge helps healthcare professionals make informed decisions when prescribing medications and treating endocrine disorders. It also underscores the importance of precise medication selection based on the specific hormonal imbalances or deficiencies present in a patient.
Question 5 of 5
Who is least likely to be treated with somatropin?
Correct Answer: A
Rationale: The correct answer is A) A 3-year-old cow on a dairy farm is least likely to be treated with somatropin. Somatropin is a synthetic form of human growth hormone used to treat growth hormone deficiency in humans. Cows do not have the same growth hormone deficiencies or genetic conditions that would necessitate the use of somatropin as in human patients. Option B) A 4-year-old girl with an XO genetic genotype has Turner syndrome, a condition that often results in short stature and may benefit from somatropin treatment to support growth. Option C) A 4-year-old boy with chronic renal failure and growth deficiency may require somatropin to help address growth issues associated with his condition. Option D) A 10-year-old boy with polydipsia and polyuria may have diabetes insipidus or another endocrine disorder that could potentially benefit from somatropin treatment to address growth issues. Educationally, understanding the appropriate use of somatropin based on underlying conditions and growth hormone deficiencies is crucial for healthcare providers to make informed treatment decisions for their patients. It is essential to consider the individual's medical history, genetic conditions, and endocrine disorders when determining the suitability of somatropin therapy.